The Effects of Individual Psychotherapy in BDNF Levels of Patients With Mental Disorders: A Systematic Review

Claudino, Felipe César de Almeida; Gonçalves, Leonardo; Schuch, Felipe Barreto; Martins, Hugo Roberto Sampaio; Rocha, Neusa Sica da

doi:10.3389/fpsyt.2020.00445

Cited by 10 publications

(10 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mechanisms that mediate stress-induced behavioral abnormalities are largely unknown. The dysfunctions of the endocrine system, oxidative stress, and neurotrophic factor can be used to explain the pathogenesis of stress-induced psychological disorders ( Claudino et al, 2020 ; McEwen and Akil, 2020 ; Satoh, 2021 ). Myricetin administration (50 mg/kg, i. p., 21 days) has been shown to reduce repeated restraint stress-induced increases in immobility time in mice in the forced swimming and tail suspension test likely through reducing the plasma corticosterone levels and increasing hippocampal GSP-Px activity and BDNF expression in the hippocampus ( Ma et al, 2015 ).…”

Section: The Other Pharmacological Effects Of Myricetin In the Nervous Systemmentioning

confidence: 99%

Pharmacological Actions of Myricetin in the Nervous System: A Comprehensive Review of Preclinical Studies in Animals and Cell Models

Xiang

Huang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Myricetin is a natural flavonoid extracted from a variety of plants, such as medicinal herbs, vegetables, berries, and tea leaves. A growing body of evidence has reported that myricetin supplementation display therapeutic activities in a lot of nervous system disorders, such as cerebral ischemia, Alzheimer’s disease, Parkinson’s disease, epilepsy, and glioblastoma. Myricetin supplementation can also protect against pathological changes and behavioral impairment induced by multiple sclerosis and chronic stress. On the basis of these pharmacological actions, myricetin could be developed as a potential drug for the prevention and/or treatment of nervous system disorders. Mechanistic studies have shown that inhibition of oxidative stress, cellular apoptosis, and neuroinflammatory response are common mechanisms for the neuroprotective actions of myricetin. Other mechanisms, including the activation of the nuclear factor E2-related factor 2 (Nrf2), extracellular signal-regulated kinase 1/2 (ERK1/2), protein kinase B (Akt), cyclic adenosine monophosphate-response element binding protein (CREB), and brain-derived neurotrophic factor (BDNF) signaling, inhibition of intracellular Ca2+ increase, inhibition of c-Jun N-terminal kinase (JNK)-p38 activation, and suppression of mutant protein aggregation, may also mediate the neuroprotective effects of myricetin. Furthermore, myricetin treatment has been shown to promote the activation of the inhibitory neurons in the hypothalamic paraventricular nucleus, which subsequently produces anti-epilepsy effects. In this review, we make a comprehensive understanding about the pharmacological effects of myricetin in the nervous system, aiming to push the development of myricetin as a novel drug for the treatment of nervous system disorders.

show abstract

Section: The Other Pharmacological Effects Of Myricetin In the Nervous Systemmentioning

confidence: 99%

Pharmacological Actions of Myricetin in the Nervous System: A Comprehensive Review of Preclinical Studies in Animals and Cell Models

Xiang

Huang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Our literature review is also incongruent with a recent systematic review of psychotherapy influence on BDNF expression. Claudino et al [ 44 ] stated that there was initial evidence for the role of BDNF as an individual psychotherapy response biomarker [ 44 ]. However, they counted statistically insignificant changes as important.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, physical activity is known to positively influence BDNF levels [ 41 ], increasing its expression, probably through epigenetic modification [ 42 , 43 ]. The change of BDNF concentration during individual psychotherapy was recently studied in a review by Claudino et al [ 44 ]; however, the review excluded studies in which group psychotherapy was used, as well as studies in which methylation of BDNF promoter gene was measured. The latter seems important, as disentangling the direct mechanism of action may be essential to clinical practice, for example, providing clues to combining multiple therapeutic approaches.…”

Section: Introductionmentioning

confidence: 99%

The Influence of Psychotherapy on Peripheral Brain-Derived Neurotrophic Factor Concentration Levels and Gene Methylation Status: A Systematic Review

Piotrkowicz

Janoska-Jaździk

Koweszko

et al. 2021

JCM

View full text Add to dashboard Cite

Psychotherapy is a well-established method of treating many mental disorders. It has been proven that psychotherapy leads to structural and functional changes in the brain; however, knowledge about the molecular and cellular mechanisms of these changes is limited. Neuroplasticity and one of its mediators, brain-derived neurotrophic factor (BDNF), are potential research targets in this field. To define the role of BDNF concentration in serum, or in plasma, and BDNF promoter gene methylation in saliva or leucocytes, in psychotherapy, an extensive literature search was conducted in the PubMed and Web of Science databases. The literature review was conducted based on papers published up until May 2021 that included pre and post psychotherapy measurements of either BDNF concentration levels or promoter gene methylation status. Ten studies were indicated as eligible for analysis: eight studies that investigated peripheral BDNF concentration levels, one study that investigated methylation status, and one study that included an evaluation of both subject matters. Patients underwent cognitive behavioral therapy or interpersonal psychotherapy. Patients were diagnosed with borderline personality disorder, major depressive disorder, anorexia nervosa, bulimia nervosa, or post-traumatic stress disorder. There were only three of the nine studies that showed statistically significant increases in BDNF concentration levels after psychotherapy. The two studies that involved BDNF gene methylation status showed a decrease in methylation after dialectical behavioral therapy of borderline patients.

show abstract

“…These findings indicate a significant association between neuroplasticity and antidepressant effect mode of action, which implies that the impact of plasticity is conveyed, at least in part, by the BDNF signal [36]. On the other hand, in a recent systematic review assessing the impact of psychotherapy on the levels of BDNF in patients with psychiatric disorders, they found a small amount of research examining the impact of psychotherapies on BDNF and concluded that patients who had only psychotherapy had no rise in BDNF levels; however, those who received concomitant medications had a much greater rise compared to those who had only pharmacological treatment [56]. BDNF was associated with some demographic characteristics of MDD patients like age, sex, family history, and disease duration in the present study.…”

Section: Discussionmentioning

confidence: 99%

Serum BDNF and suicidal ideation in drug-naïve and drug-treated MDD patients: a case–control study

Yousef

El-deen

Ibrahim

et al. 2021

Egypt J Neurol Psychiatry Neurosurg

View full text Add to dashboard Cite

Background Disturbances in structural and synaptic plasticity have been linked to depression and suicidal ideation. One of the major neurotrophic factors, the brain-derived neurotrophic factor (BDNF), is involved in the maintenance and survival of neurons and synaptic plasticity. This case–control study assesses the serum BDNF and suicidal ideation among drug-naïve and drug-treated MDD patients attending university hospitals and comparing them to healthy control. A simple random sample of 57 MDD patients and 57 age- and sex-comparable controls were enrolled. The researchers conducted a semi-structured interview to collect the demographic characteristics and disease history. Structured Clinical Interview for DSM-5 (SCID-5), Hamilton Depression Rating Scale (HDRS), and Beck Scale for Suicidal Ideation (BSS) were applied to the participants. Blood samples were collected to measure plasma BDNF level. Results The MDD group had lower BDNF than the control group. Within the MDD group, drug-naïve patients had significantly lower BDNF than drug-treated patients. Female patients had lower BDNF than male patients. Positive family history of MDD was associated with low BDNF. Severe and moderate cases had lower BDNF than mild cases. High BSS (≥24) was associated with low BDNF. A statistically significant positive correlation was found between BDNF and age, disease duration, duration of the current episode, and the number of previous episodes. On the other hand, a statistically significant negative correlation was found between BDNF and age of MDD onset, HDRS, and BSS. A regression model was highly statistically significant in the prediction of HDRS. BDNF and disease duration were negatively correlated with HDRS. On the other hand, depression treatment status was not significantly associated with the HDRS prediction model. Conclusion Our findings extend the neurotrophic concept of depression by identifying the decreased BDNF levels as a peripheral biomarker of MDD. Our assessment of depression and suicidal ideation (SI) and their relationship to decreased BDNF levels shed light on the etiopathology of MDD and its related suicidality. They should be more studied to understand better the mechanisms by which they develop. To further explore the effect of BDNF in suicide, larger study sizes and a range of psychiatric diagnoses associated with suicide attempts are required.

show abstract

The Effects of Individual Psychotherapy in BDNF Levels of Patients With Mental Disorders: A Systematic Review

Cited by 10 publications

References 59 publications

Pharmacological Actions of Myricetin in the Nervous System: A Comprehensive Review of Preclinical Studies in Animals and Cell Models

Pharmacological Actions of Myricetin in the Nervous System: A Comprehensive Review of Preclinical Studies in Animals and Cell Models

The Influence of Psychotherapy on Peripheral Brain-Derived Neurotrophic Factor Concentration Levels and Gene Methylation Status: A Systematic Review

Serum BDNF and suicidal ideation in drug-naïve and drug-treated MDD patients: a case–control study

Contact Info

Product

Resources

About